<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04949139</url>
  </required_header>
  <id_info>
    <org_study_id>B-2104-680-003</org_study_id>
    <nct_id>NCT04949139</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Rapid Intermittent Correction Compared With Slow Continuous Correction in Patients With Severe Hypernatremia</brief_title>
  <acronym>SALSAII</acronym>
  <official_title>Efficacy and Safety of Rapid Intermittent Correction Compared With Slow Continuous Correction in Patients With Severe Hypernatremia (SALSA II Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy and safety of rapid intermittent correction and slow&#xD;
      correction with an electrolyte-free solution in patients with severe hypernatremia&#xD;
      (glucose-corrected serum sodium, ≥ 155 mmol/L).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypernatremia is defined as serum sodium (sNa) levels above 145 mmol/L and is caused by&#xD;
      abnormalities in water balance, mainly in children, elderly, and critically ill patients. It&#xD;
      occurs in 3% of hospitalized patients and in 9% of critically ill patients. Hypernatremia&#xD;
      indicates hypertonic hyperosmolality and causes water outflow, resulting in cell dehydration.&#xD;
      Most of the symptoms and signs of hypernatremia are due to brain abnormalities, which can&#xD;
      progress to hyperventilation, muscle weakness, consciousness (lethargy), and coma. The&#xD;
      short-term mortality rate of hypernatremia is 50%-60%. Decreased osmotic pressure in the&#xD;
      extracellular fluid during correction of hyponatremia can cause cellular edema and permanent&#xD;
      brain damage. The recommended sNa correction rate for acute hypernatremia is up to 1&#xD;
      mmol/L/h, whereas that for chronic hypernatremia is less than 0.5 mmol/L/h (approximately 10&#xD;
      mmol/L/day). However, these correction rates have only been studied and proven in pediatric&#xD;
      patients. A recent study conducted on adults revealed that rapid correction (more than 0.5&#xD;
      mmol/L/h) was not associated with a higher risk for mortality, seizures, and alteration of&#xD;
      consciousness. Several studies reported that excessively slow rates of sNa correction were&#xD;
      associated with higher mortality, whereas rapid rates demonstrated lower mortality. There are&#xD;
      no established guidelines for the Na correction rate for hypernatremia. The European and&#xD;
      American guidelines recommend infusion of electrolyte-free water (10 mL/kg over 1 h or 3&#xD;
      mL/kg/h) for the management of overcorrection of hyponatremia. In the previously published&#xD;
      SALSA I trial, 10 mL/kg over 1 h was applied as a method of re-lowering treatment in overly&#xD;
      rapid correction of hyponatremia. However, this rapid intermittent bolus of electrolyte-free&#xD;
      water has never been applied to treat hypernatremia.&#xD;
&#xD;
      The aim of this prospective, randomized, open-labeled, multi-center, and&#xD;
      investigator-initiated trial is to determine whether a rapid and intermittent bolus of&#xD;
      electrolyte-free water in hypernatremia can increase the incidence of rapid decrease in sNa&#xD;
      level and increase the survival time compared to the slow continuous administration method. A&#xD;
      total of 166 patients with severe hypernatremia will be enrolled and randomly assigned to&#xD;
      receive either intermittent bolus or slow continuous infusion of 5% dextrose water. The&#xD;
      participants will be divided into three groups according to age and sex and will receive 5%&#xD;
      dextrose water for 2 days at different correction rates. Serum sodium will be measured every&#xD;
      3 h from the beginning to 6 h, followed by every 6 h until 48 h. In addition, urine sodium&#xD;
      and potassium levels will be measured at baseline and 24 h.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2021</start_date>
  <completion_date type="Anticipated">May 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2026</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of rapid change in sNa level within 24 hours defined as follows</measure>
    <time_frame>up to 24 hours</time_frame>
    <description>Change in sNa by ≥ 6 mmol/L or Na ≤ 150 mmol/L within 24 hours All subjects will receive 5% dextrose water by rapid intermittent bolus or slow continuous infusion for 48 h, and sNa levels will be measured.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of 28 days survival</measure>
    <time_frame>up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delta of sodium level at 6 hours from the initial level</measure>
    <time_frame>up to 6 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of infused 5% dextrose water</measure>
    <time_frame>up to 48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of rapid change in sNa level within 48 hours defined as follows</measure>
    <time_frame>up to 48 hours</time_frame>
    <description>Change in sNa by ≥ 12 mmol/L or Na ≤ 150 mmol/L within 48 hours</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Target correction rate</measure>
    <time_frame>up to 48 hours</time_frame>
    <description>Change in Na by ≥ 6 mmol/L and &lt; 12 mmol/L from the initial level or Na ≤ 150 mmol/L within 24 hours Change in Na by ≥ 12 mmol/L and &lt; 24 mmol/L from the initial level or Na ≤ 150 mmol/L within 48 hours</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of undercorrection:</measure>
    <time_frame>up to 48 hours</time_frame>
    <description>sNa &lt; 6 mmol/L within 3/6/12/24 hours sNa &lt; 12 mmol/L within 48 h</description>
  </other_outcome>
  <other_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>up to 8 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of uses of desmopressin</measure>
    <time_frame>up to 48 hours</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of overcorrection</measure>
    <time_frame>up to 48 hours</time_frame>
    <description>Na &gt; 12 mmol/L within 24 h or &gt; 24 mmol/L within 48 h at any given period</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of cerebral edema documented via brain CT at 48 hours in patients with overcorrection</measure>
    <time_frame>up to 48 hours</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of osmotic demyelinating syndrome confirmed by ICD-10 code or MRI</measure>
    <time_frame>up to 48 hours</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Glasgow coma scale at pretreatment, 24 hours, and 48 hours</measure>
    <time_frame>up to 48 hours</time_frame>
    <description>Glasgow coma scale can range from 3 (completely unresponsive) to 15 (responsive).</description>
  </other_outcome>
  <other_outcome>
    <measure>In-hospital mortality</measure>
    <time_frame>up to 28 days</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">166</enrollment>
  <condition>Hypernatremia</condition>
  <arm_group>
    <arm_group_label>Rapid intermittent bolus group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A : males &lt; 65 ; B : females &lt; 65 or males ≥ 65 ; C : females ≥ 65 yrs&#xD;
&lt;During the first 3 h&gt;&#xD;
Primary treatment over 1h A: 5DW 8 B: 5DW 7 C: 5DW 6 mL/kg&#xD;
If undercorrected, Repeat the 5DW amount infused during primary treatment after 3 h&#xD;
&lt;At 3-24 h&gt; Modify protocol based on sNa at each time point (6/12/18/24 h)&#xD;
Check U/S ratio at 0 h&#xD;
undercorrection &lt; 0.5: repeat the amount infused during primary treatment q 3 h&#xD;
≥ 0.5: repeat the amount infused during primary treatment q 6 h&#xD;
target correction &lt; 0.5: repeat the amount infused during primary treatment q 6 h ≥ 0.5: stop the infusion&#xD;
&lt;At 24-48 h&gt; Modify protocol based on sNa at each time point (30/36/42/48 h)&#xD;
Check U/S ratio at 24 h&#xD;
undercorrection &lt; 0.5: repeat the amount infused during primary treatment q 3 h&#xD;
≥ 0.5: repeat the amount infused during primary treatment q 6 h&#xD;
target correction &lt; 0.5: repeat the amount infused during primary treatment q 6 h ≥ 0.5: stop the infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Slow continuous infusion group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will be divided into three groups same as above&#xD;
&lt;During the first 3 h&gt;&#xD;
Primary treatment A: 5DW 1.8 B: 5DW 1.57 C: 5DW 1.35 mL/kg/h&#xD;
Modify protocol as described below based on sNa measurement at 3 h&#xD;
undercorrection: maintain the infusion rate&#xD;
target correction: stop the infusion&#xD;
&lt;At 3-24 h&gt; Modify protocol based on sNa measurement at each time point (6/12/18/24 h)&#xD;
Check U/S ratio at 0 h&#xD;
• undercorrection&#xD;
&lt; 0.5: increase the infusion rate to twice that of the primary treatment&#xD;
≥ 0.5: maintain the infusion rate&#xD;
• target correction&#xD;
&lt; 0.5: maintain the infusion rate&#xD;
≥ 0.5: stop the infusion&#xD;
&lt;At 24-48 h&gt; Modify protocol based on sNa measurement at each time point (30/36/42/48 h)&#xD;
Check U/S ratio at 24 h&#xD;
• undercorrection&#xD;
&lt; 0.5: increase the infusion rate to twice that of the primary treatment&#xD;
≥ 0.5: maintain the infusion rate&#xD;
• target correction&#xD;
&lt; 0.5: maintain the infusion rate&#xD;
≥ 0.5: stop the infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dextrose 5% in water</intervention_name>
    <description>Reducing the sodium concentration</description>
    <arm_group_label>Rapid intermittent bolus group</arm_group_label>
    <arm_group_label>Slow continuous infusion group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who visit the emergency department and in-patients over 18 years&#xD;
&#xD;
          -  Severe hypernatremia: glucose-corrected serum sodium ≥ 155 mmol/L&#xD;
&#xD;
          -  Written consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Arterial hypotension requiring inotropes or vasopressors (systolic blood pressure &lt; 90&#xD;
             mmHg and mean arterial pressure &lt; 70 mmHg)&#xD;
&#xD;
          -  Anuria or bilateral urinary outlet obstruction&#xD;
&#xD;
          -  Uncontrolled diabetes mellitus (HbA1C &gt; 9%) or glucose at baseline &gt; 500 mg/dL or&#xD;
             diabetic ketoacidosis or hyperosmolar hyperglycemic syndrome&#xD;
&#xD;
          -  Decompensated liver cirrhosis (LC) - Known LC with ascites or diuretic use or hepatic&#xD;
             encephalopathy or varix&#xD;
&#xD;
          -  End-stage renal disease receiving renal replacement therapy&#xD;
&#xD;
          -  Women who are pregnant or breast feeding&#xD;
&#xD;
          -  Patients with the following conditions within 30 days prior to randomization:&#xD;
&#xD;
               1. History of cardiac surgery excluding PCA, acute myocardial infarction, sustained&#xD;
                  ventricular tachycardia, ventricular fibrillation, acute coronary syndrome, and&#xD;
                  admission for heart failure&#xD;
&#xD;
               2. Uncontrolled increase of intracranial pressure&#xD;
&#xD;
          -  The subjects judged by investigators to have difficulty continuing the trial were also&#xD;
             excluded.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sejoong Kim, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Seoul National University Bundang Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sejoong Kim, PhD</last_name>
    <phone>+821094964899</phone>
    <email>sejoong2@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Seon Ha Baek, PhD</last_name>
    <phone>+821033442490</phone>
    <email>seonhabaek@hallym.or.kr</email>
  </overall_contact_backup>
  <reference>
    <citation>Qian Q. Hypernatremia. Clin J Am Soc Nephrol. 2019 Mar 7;14(3):432-434. doi: 10.2215/CJN.12141018. Epub 2019 Feb 6.</citation>
    <PMID>30728169</PMID>
  </reference>
  <reference>
    <citation>Chauhan K, Pattharanitima P, Patel N, Duffy A, Saha A, Chaudhary K, Debnath N, Van Vleck T, Chan L, Nadkarni GN, Coca SG. Rate of Correction of Hypernatremia and Health Outcomes in Critically Ill Patients. Clin J Am Soc Nephrol. 2019 May 7;14(5):656-663. doi: 10.2215/CJN.10640918. Epub 2019 Apr 4.</citation>
    <PMID>30948456</PMID>
  </reference>
  <reference>
    <citation>Hillier TA, Abbott RD, Barrett EJ. Hyponatremia: evaluating the correction factor for hyperglycemia. Am J Med. 1999 Apr;106(4):399-403.</citation>
    <PMID>10225241</PMID>
  </reference>
  <reference>
    <citation>Adrogué HJ, Madias NE. Hypernatremia. N Engl J Med. 2000 May 18;342(20):1493-9. Review.</citation>
    <PMID>10816188</PMID>
  </reference>
  <reference>
    <citation>Sterns RH. Evidence for Managing Hypernatremia: Is It Just Hyponatremia in Reverse? Clin J Am Soc Nephrol. 2019 May 7;14(5):645-647. doi: 10.2215/CJN.02950319. Epub 2019 Apr 4.</citation>
    <PMID>31064771</PMID>
  </reference>
  <reference>
    <citation>Cabassi A, Tedeschi S. Severity of community acquired hypernatremia is an independent predictor of mortality: a matter of water balance and rate of correction. Intern Emerg Med. 2017 Oct;12(7):909-911. doi: 10.1007/s11739-017-1693-x. Epub 2017 Jul 1.</citation>
    <PMID>28669048</PMID>
  </reference>
  <reference>
    <citation>Lindner G, Funk GC. Hypernatremia in critically ill patients. J Crit Care. 2013 Apr;28(2):216.e11-20. doi: 10.1016/j.jcrc.2012.05.001. Epub 2012 Jul 2. Review.</citation>
    <PMID>22762930</PMID>
  </reference>
  <reference>
    <citation>Bataille S, Baralla C, Torro D, Buffat C, Berland Y, Alazia M, Loundou A, Michelet P, Vacher-Coponat H. Undercorrection of hypernatremia is frequent and associated with mortality. BMC Nephrol. 2014 Feb 21;15:37. doi: 10.1186/1471-2369-15-37.</citation>
    <PMID>24559470</PMID>
  </reference>
  <reference>
    <citation>Alshayeb HM, Showkat A, Babar F, Mangold T, Wall BM. Severe hypernatremia correction rate and mortality in hospitalized patients. Am J Med Sci. 2011 May;341(5):356-60. doi: 10.1097/MAJ.0b013e31820a3a90.</citation>
    <PMID>21358313</PMID>
  </reference>
  <reference>
    <citation>Sterns RH, Silver SM. Salt and water: read the package insert. QJM. 2003 Aug;96(8):549-52.</citation>
    <PMID>12897339</PMID>
  </reference>
  <reference>
    <citation>Spasovski G, Vanholder R, Allolio B, Annane D, Ball S, Bichet D, Decaux G, Fenske W, Hoorn EJ, Ichai C, Joannidis M, Soupart A, Zietse R, Haller M, van der Veer S, Van Biesen W, Nagler E; Hyponatraemia Guideline Development Group. Clinical practice guideline on diagnosis and treatment of hyponatraemia. Eur J Endocrinol. 2014 Feb 25;170(3):G1-47. doi: 10.1530/EJE-13-1020. Print 2014 Mar. Erratum in: Eur J Endocrinol. 2014 Jul;171(1):X1.</citation>
    <PMID>24569125</PMID>
  </reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>June 6, 2021</study_first_submitted>
  <study_first_submitted_qc>June 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2021</study_first_posted>
  <last_update_submitted>June 24, 2021</last_update_submitted>
  <last_update_submitted_qc>June 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypernatremia</keyword>
  <keyword>Treatment</keyword>
  <keyword>5% dextrose water</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypernatremia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

